Cholinesterase Inhibitor News and Research

RSS
Since the introduction of the first cholinesterase inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, donepezil, galantamine and rivastigmine, to be the first line pharmacotherapy for mild to moderate Alzheimer's disease. The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme acetylcholinesterase.
First patient recruited for UK-wide Parkinson's disease trial

First patient recruited for UK-wide Parkinson's disease trial

Improving dementia treatment and staff training in care homes saves thousands of pounds per year

Improving dementia treatment and staff training in care homes saves thousands of pounds per year

Bath geriatrician leads new UK-wide trial into Parkinson’s disease

Bath geriatrician leads new UK-wide trial into Parkinson’s disease

Researchers explore patient adherence, tolerability to class of Alzheimer's drugs

Researchers explore patient adherence, tolerability to class of Alzheimer's drugs

Cholinesterase inhibitor delays nursing home admission in late-stage AD

Cholinesterase inhibitor delays nursing home admission in late-stage AD

Anti-dementia drugs could result in harmful weight loss, say researchers

Anti-dementia drugs could result in harmful weight loss, say researchers

Study looks at impact of amyloid imaging on diagnosis, management of patients with cognitive impairment

Study looks at impact of amyloid imaging on diagnosis, management of patients with cognitive impairment

FDA approves Novartis’ Exelon Patch to treat mild to moderate AD

FDA approves Novartis’ Exelon Patch to treat mild to moderate AD

Yissum Research and other investors complete additional investment round of $3 million in Avraham Pharmaceuticals

Yissum Research and other investors complete additional investment round of $3 million in Avraham Pharmaceuticals

Researchers identify abnormal hippocampal blood flow in veterans with Gulf War illness

Researchers identify abnormal hippocampal blood flow in veterans with Gulf War illness

Positive results from first human masitinib phase 2 study in Alzheimer's disease published in peer-reviewed journal

Positive results from first human masitinib phase 2 study in Alzheimer's disease published in peer-reviewed journal

Common Alzheimer's disease drug enhances learning of new skills

Common Alzheimer's disease drug enhances learning of new skills

FDA approves NAMENDA XR for treatment of Alzheimer's type dementia

FDA approves NAMENDA XR for treatment of Alzheimer's type dementia

No scientific proof that patients with Alzheimer's disease benefit from drugs containing the agent memantine

No scientific proof that patients with Alzheimer's disease benefit from drugs containing the agent memantine

Bradycardia more likely in patients taking cholinesterase inhibitors

Bradycardia more likely in patients taking cholinesterase inhibitors

MemoryXL improves cognitive performance in Alzheimer's disease

MemoryXL improves cognitive performance in Alzheimer's disease

Dementia drugs Aricept, Exelon and Reminyl may put some patients at risk

Dementia drugs Aricept, Exelon and Reminyl may put some patients at risk

Non-drug treatment of Alzheimer's disease: Long-term benefit not proven

Non-drug treatment of Alzheimer's disease: Long-term benefit not proven

Cholinesterase inhibitors safe and effective therapy for behavioral and psychological symptoms of dementia

Cholinesterase inhibitors safe and effective therapy for behavioral and psychological symptoms of dementia

Dual treatment of incontinence and dementia associated with functional decline

Dual treatment of incontinence and dementia associated with functional decline